Literature DB >> 21685500

Deficiency of PXR decreases atherosclerosis in apoE-deficient mice.

Yipeng Sui1, Jinxian Xu, Jennifer Rios-Pilier, Changcheng Zhou.   

Abstract

The pregnane X receptor (PXR, also known as SXR) is a nuclear hormone receptor activated by xenobiotics as well as diverse sterols and their metabolites. PXR functions as a xenobiotic sensor to coordinately regulate xenobiotic metabolism via transcriptional regulation of xenobiotic-detoxifying enzymes and transporters. Recent evidence indicates that PXR may also play an important role in lipid homeostasis and atherosclerosis. To define the role of PXR in atherosclerosis, we generated PXR and apoE double knockout (PXR(-/-)apoE(-/-)) mice. Here we show that deficiency of PXR did not alter plasma triglyceride and cholesterol levels in apoE(-/-) mice. However, PXR(-/-)apoE(-/-) mice had significantly decreased atherosclerotic cross-sectional lesion area in both the aortic root and brachiocephalic artery by 40% (P < 0.01) and 60% (P < 0.001), respectively. Interestingly, deficiency of PXR reduced the expression levels of CD36, lipid accumulation, and CD36-mediated oxidized LDL uptake in peritoneal macrophages of PXR(-/-)apoE(-/-) mice. Furthermore, immunofluorescence staining showed that PXR and CD36 were expressed in the atherosclerotic lesions of apoE(-/-) mice, and the expression levels of PXR and CD36 were diminished in the lesions of PXR(-/-)apoE(-/-) mice. Our findings indicate that deficiency of PXR attenuates atherosclerosis development, which may result from decreased CD36 expression and reduced lipid uptake in macrophages.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21685500      PMCID: PMC3151685          DOI: 10.1194/jlr.M017376

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  50 in total

1.  Transforming growth factor-beta1 (TGF-beta1) and TGF-beta2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma.

Authors:  J Han; D P Hajjar; J M Tauras; J Feng; A M Gotto; A C Nicholson
Journal:  J Biol Chem       Date:  2000-01-14       Impact factor: 5.157

2.  Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver.

Authors:  Nadine Albermann; Friedrich Hubertus Schmitz-Winnenthal; Kaspar Z'graggen; Christine Volk; Michael Marcus Hoffmann; Walter Emil Haefeli; Johanna Weiss
Journal:  Biochem Pharmacol       Date:  2005-09-15       Impact factor: 5.858

3.  A CD36-dependent signaling cascade is necessary for macrophage foam cell formation.

Authors:  S Ohidar Rahaman; David J Lennon; Maria Febbraio; Evgeny A Podrez; Stanley L Hazen; Roy L Silverstein
Journal:  Cell Metab       Date:  2006-09       Impact factor: 27.287

Review 4.  Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection.

Authors:  Giuseppe Barbaro
Journal:  Curr HIV Res       Date:  2006-01       Impact factor: 1.581

5.  Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA.

Authors:  Andrew Owen; Becky Chandler; Dave J Back; Saye H Khoo
Journal:  Antivir Ther       Date:  2004-10

6.  The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations.

Authors:  S D Shafran; L D Mashinter; S E Roberts
Journal:  HIV Med       Date:  2005-11       Impact factor: 3.180

7.  Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice.

Authors:  Kathryn J Moore; Vidya V Kunjathoor; Stephanie L Koehn; Jennifer J Manning; Anita A Tseng; Jessica M Silver; Mary McKee; Mason W Freeman
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

8.  SXR, a novel steroid and xenobiotic-sensing nuclear receptor.

Authors:  B Blumberg; W Sabbagh; H Juguilon; J Bolado; C M van Meter; E S Ong; R M Evans
Journal:  Genes Dev       Date:  1998-10-15       Impact factor: 11.361

Review 9.  Going nuclear in metabolic and cardiovascular disease.

Authors:  Christopher K Glass
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

10.  A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway.

Authors:  Jie Zhou; Yonggong Zhai; Ying Mu; Haibiao Gong; Hirdesh Uppal; David Toma; Songrong Ren; Ronald M Evans; Wen Xie
Journal:  J Biol Chem       Date:  2006-03-23       Impact factor: 5.157

View more
  32 in total

Review 1.  Microbial modulation of cardiovascular disease.

Authors:  J Mark Brown; Stanley L Hazen
Journal:  Nat Rev Microbiol       Date:  2018-01-08       Impact factor: 60.633

2.  Intestinal pregnane X receptor links xenobiotic exposure and hypercholesterolemia.

Authors:  Yipeng Sui; Robert N Helsley; Se-Hyung Park; Xiulong Song; Zun Liu; Changcheng Zhou
Journal:  Mol Endocrinol       Date:  2015-03-26

Review 3.  Novel functions of PXR in cardiometabolic disease.

Authors:  Changcheng Zhou
Journal:  Biochim Biophys Acta       Date:  2016-02-26

4.  Perinatal Bisphenol A Exposure Increases Atherosclerosis in Adult Male PXR-Humanized Mice.

Authors:  Yipeng Sui; Se-Hyung Park; Fang Wang; Changcheng Zhou
Journal:  Endocrinology       Date:  2018-04-01       Impact factor: 4.736

5.  Myeloid-specific IκB kinase β deficiency decreases atherosclerosis in low-density lipoprotein receptor-deficient mice.

Authors:  Se-Hyung Park; Yipeng Sui; Florence Gizard; Jinxian Xu; Jennifer Rios-Pilier; Robert N Helsley; Seong-Su Han; Changcheng Zhou
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09-27       Impact factor: 8.311

6.  RBCK1, an E3 ubiquitin ligase, interacts with and ubiquinates the human pregnane X receptor.

Authors:  Ritu Rana; Sherry Coulter; Harriet Kinyamu; Joyce A Goldstein
Journal:  Drug Metab Dispos       Date:  2012-11-15       Impact factor: 3.922

Review 7.  Targeting xenobiotic receptors PXR and CAR for metabolic diseases.

Authors:  Jie Gao; Wen Xie
Journal:  Trends Pharmacol Sci       Date:  2012-08-10       Impact factor: 14.819

Review 8.  PXR antagonists and implication in drug metabolism.

Authors:  Sridhar Mani; Wei Dou; Matthew R Redinbo
Journal:  Drug Metab Rev       Date:  2013-02       Impact factor: 4.518

9.  Myeloid-specific deficiency of pregnane X receptor decreases atherosclerosis in LDL receptor-deficient mice.

Authors:  Yipeng Sui; Zhaojie Meng; Se-Hyung Park; Weiwei Lu; Christopher Livelo; Qi Chen; Tong Zhou; Changcheng Zhou
Journal:  J Lipid Res       Date:  2020-03-13       Impact factor: 5.922

Review 10.  Bile acid signaling in metabolic disease and drug therapy.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Pharmacol Rev       Date:  2014-10       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.